Anemia is the most common and persistent hematological abnormality in oncology patients. Chemotherapy-induced anemia (CIA) is a consequence of malignant invasion of normal tissue leading to blood loss, bone marrow infiltration with disruption of erythropoiesis, and functional iron deficiency as a consequence of inflammation. Fatigue is the most common symptom of CIA, although vertigo, loss of appetite, poor concentration, and dyspnea are also frequently reported. Grade of anemia in combination with type of cancer and baseline cardiopulmonary function contribute to symptom severity.

 

The risk and severity of anemia during chemotherapy vary significantly depending on the type, schedule, and intensity of treatments, and whether the patient has received previous myelosuppressive chemotherapy or radiation therapy, as well as the patient’s underlying medical conditions. Current practices to treat CIA include packed red blood cell transfusions, erythropoietin stimulating agents (ESAs), and iron supplementation. In addition to novel screening mechanisms, various hormones and pharmacologic agents influence the prevention and management of CIA. Novel treatment options, along with increasing awareness regarding CIA, are responsible for the growth of the therapeutic market.

 

 

 

 

 

 

The Chemotherapy Induced Anemia epidemiology division provide insights about historical and current Chemotherapy Induced Anemia patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

 

 

1. A study by Garry H Lyman et al. conducted on US cohort that studied the adjusted mean 6-month expenditure for the average anemic patient receiving chemotherapy stated that , if anemic patients had the same average health status as nonanemic patients, their predicted 6-month expenditures would have been 19% lower

 

2. A study titled “Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer” specified that under fixed dosing, the average cost of biosimilar epoetin α treatment across scenarios was ~4500 USD to  8500 USD. Corresponding estimates were ~10,000 USD for originator epoetin α, ~12,000 USD for epoetin β, ~13,000 USD for darbepoetin α once weekly, and ~13,000 USD for darbepoetin α once every 3 weeks.

 

 

1. Chemotherapy Induced Anemia market report covers a descriptive overview and comprehensive insight of the Chemotherapy Induced Anemia epidemiology Chemotherapy Induced Anemia market in the 7MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. Chemotherapy Induced Anemia market report provides insights on the current and emerging therapies. 

3. Chemotherapy Induced Anemia market report offers a global historical and forecasted market covering drug outreach in 7MM.

4. Chemotherapy Induced Anemia market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Chemotherapy Induced Anemia market.

 

 

 

 

 

 

 

 

1. Key Insights

2. Executive Summary of Chemotherapy Induced Anemia

3. Competitive Intelligence Analysis for Chemotherapy Induced Anemia

4. Chemotherapy Induced Anemia: Market Overview at a Glance

5.  Chemotherapy Induced Anemia: Disease Background and Overview

6. Patient Journey

7. Chemotherapy Induced Anemia Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Chemotherapy Induced Anemia Treatment

11. Marketed Products

12. Emerging Therapies

13. Chemotherapy Induced Anemia: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Chemotherapy Induced Anemia

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

 

• The report will help in developing business strategies by understanding trends shaping and driving the Chemotherapy Induced Anemia market
• To understand the future market competition in the Chemotherapy Induced Anemia market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy Induced Anemia in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Chemotherapy Induced Anemia market
• To understand the future market competition in the Chemotherapy Induced Anemia market

Related Reports:- 

1. Chemotherapy-induced peripheral neuropathy – Market Insight, Epidemiology and Market Forecast -2030

 

2. Chemotherapy Induced Febrile Neutropenia – Epidemiology Forecast to 2030